Phase 3 N=38 A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Crohns Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 33 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,110 Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
Respiratory Syncytial Virus Infections
Primary: Adjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 Vaccination — 74.7; 110.8; 88.5; 116.2 Titers
Phase 3 N=66 Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 64; 7 Participants
Phase 3 N=61 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Type 1 Diabetes · Peripheral Neuropathy
Primary: Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh — 12; 14 Percentage change in IENFD
Phase 3 N=227 Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Uveitis
Primary: Corticosteroid-sparing Treatment Success Within the First 6 Months After Randomization — 0.69; 0.54 Cumulative proportion of participants — p=0.029
Phase 3 N=11 Impact of Switching to Continuous Release Dopamine Agonists
Parkinson Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS), Parts 3 (Motor Performance) and 4 (Disability). — 19.2; 17.6; 5.1; 2.9 score on a scale
Phase 3 N=928 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Diabetes · Type 2 Diabetes
Primary: Change From Baseline in HbA1c at Week 52 [Noninferiority Analysis] — -1.26; -1.17 Percentage of HbA1c
Phase 3 N=1,758 Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa
Human Immunodeficiency Virus · Depression · Sexually Transmitted Diseases
Primary: Prevalence of HIV and/or Chlamydia and/or Gonorrhoeae — 60; 70 Participants
Phase 3 N=49 Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
COVID-19
Primary: Number of Subjects Experiencing TEAEs — 16; 12; 9; 2 Participants
Phase 3 N=270 A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.
Hyperkalemia
Primary: Least Square Mean S-K Level on Days 8-29 — 4.859; 4.440; 5.225 mmol/L — p=<0.001
Phase 3 N=1 CEUS Evaluation of Hypoxic Ischemic Injury
Hypoxic-Ischemic Encephalopathy · Brain Ischemia Hypoxia
Primary: Detection of Brain Perfusion Abnormalities Using Contrast-enhanced Ultrasound — 1; 0 Participants
Phase 3 N=1,030 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Follicular Lymphoma
Primary: Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review — 48.1; 53.0 Percent of participants — p=0.128
Phase 3 N=115 Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
Suspected or Documented Gram-negative Bacterial Infection
Primary: Percentage of Participants With One or More Adverse Event (AE) — 60.0; 50.0; 64.5; 36.4 Percentage of Participants
Phase 3 N=141 Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor
Neuroendocrine Tumors
Primary: First Progression Free Survival (PFS1) — 71.4; 61.8 percentage of patients alive and PD-free — p=0.229
Phase 3 N=557 Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
Migraine
Primary: Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period — -8.19; -6.62 days — p=0.015